Comparison of Two Ventilator Mode During the Night: New Strategy of Mechanical Ventilation Weaning
Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Apr 5, 2012
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patient and/or legal representative of the patient has provided a written informed consent before inclusion in the study
- • The patients is hospitalized in respiratory and critical care unit (university hospital of AMIENS, FRANCE)
- • the patient is mechanically ventilated (ventilator model : puritan-bennett B840)
- • Pulmonary disease,chronic obstructive (Spirometry and Blood Gas Analysis in chronic state before admission)
- • stable cardiovascular status (cardiac frequency \< 140 beats/min and systolic blood pressure : 90-160 mmHg without catecholamines)
- • midazolam \< 0,05mg/kg/h
- • sufentanyl \< 0,05µ/kg/h
- • the disorder that caused respiratory failure and prompted mechanical ventilation is treated
- • the clinician suspects the patient may be ready to begin the weaning process
- • inspiratory oxygen fraction (FiO2) \< 50%
- • positive end-expiratory pressure \< or equal 8cmH2O
- • during the day, the patient tolerate pressure support ventilation (pressure support level \< 15cmH2O
- • respiratory frequency (FR) \< 35 breaths/min
- • tidal volume (VT) \> 5ml/kg
- • PaO2/FiO2 \> 200 mmHg
- • FR/VT \< 105 breaths/min/L
- Exclusion Criteria:
- • sleep apnea, central
- • narcolepsy
- • Encephalopathy, Metabolic AND Encephalitis
About Centre Hospitalier Universitaire, Amiens
The Centre Hospitalier Universitaire (CHU) Amiens is a leading academic medical center in France dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on multidisciplinary collaboration, CHU Amiens integrates patient care, education, and research to enhance treatment outcomes and improve patient quality of life. The institution is committed to ethical standards and regulatory compliance in its clinical research endeavors, aiming to contribute significantly to the medical community and the development of new therapeutic approaches. By fostering partnerships with various stakeholders, CHU Amiens strives to translate scientific discoveries into practical applications that benefit patients and healthcare systems alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amiens, , France
Patients applied
Trial Officials
ANDREJAK Claire, MD
Principal Investigator
CHU Amiens
JOUNIEAUX Vincent, MD PhD
Study Director
CHU Amiens
BASILLE Damien, MD
Principal Investigator
CHU Amiens
ROGER Pierre-Alexandre, MD
Principal Investigator
CHU Amiens
ROSE Dominique, MD
Principal Investigator
CHU Amiens
MONCONDUIT Julien, MD
Principal Investigator
CHU Amiens
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials